Lixte Biotechnology Holdings, Inc. Files 8-K

Ticker: LIXT · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1335105

Sentiment: neutral

Topics: corporate-update, 8-k

Related Tickers: LIXT

TL;DR

LIXT filed an 8-K on March 11th, updating office location and contact info. No major news.

AI Summary

Lixte Biotechnology Holdings, Inc. filed an 8-K on March 11, 2025, reporting on events that occurred on March 10, 2025. The filing indicates the company's principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California. The report also lists the company's telephone number as (631) 830-7092.

Why It Matters

This 8-K filing provides an update on the company's operational details and principal office location, which is important for investors and stakeholders to stay informed about the company's current status.

Risk Assessment

Risk Level: low — The filing is a routine update on corporate information and does not contain significant financial or operational news that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report for Lixte Biotechnology Holdings, Inc., detailing events that occurred on March 10, 2025, and providing updated corporate information.

When was this 8-K report filed with the SEC?

The 8-K report was filed on March 11, 2025.

Where are Lixte Biotechnology Holdings, Inc.'s principal executive offices located?

The principal executive offices of Lixte Biotechnology Holdings, Inc. are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.

What is the telephone number listed for Lixte Biotechnology Holdings, Inc. in this filing?

The telephone number for Lixte Biotechnology Holdings, Inc. is (631) 830-7092.

Does this filing disclose any new business developments or financial results?

Based on the provided text, this filing appears to be an update on corporate information (like office location and phone number) and does not explicitly disclose new business developments or financial results.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing